Larin Fe 1.5/30 Kit
FDA Label NDC 16714-405

56 label sections · Submitted to the FDA by Northstar Rx Llc · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Northstar Rx Llc for the product Larin Fe 1.5/30 (NDC 16714-405). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding other, warning: cigarette smoking and serious cardiovascular events, description, clinical pharmacology, pharmacokinetics, absorption, distribution, metabolism, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Label Section Quick Index

Warning: Cigarette Smoking And Serious Cardiovascular Events

Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs, including LARIN™ Fe 1.5/30, are contraindicated in women who are over 35 years of age and smoke (see CONTRAINDICATIONS and WARNINGS).

13. Hereditary Angioedema

In women with hereditary angioedema, exogenous estrogens may induce or exacerbate symptoms of angioedema.

14. Depression

Carefully observe women with a history of depression and discontinue LARINTM Fe 1.5/30 if depression recurs to a serious degree.

Package Label.Principal Display Panel

Lable Display Panel (Image 08)

Lable Display Panel (Image 08)

* Please review the disclaimer below.